| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
During the last three months, 6 analysts shared their evaluations of Healthpeak Properties (NYSE:DOC), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.5, a high estimate of $21.00, and a low estimate of $18.00. Experiencing a 13.72% decline, the current average is now lower than the previous average price target of $22.60.

A comprehensive examination of how financial experts perceive Healthpeak Properties is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jonathan Hughes | Raymond James | Announces | Outperform | $20.00 | - |
| John Kilichowski | Wells Fargo | Lowers | Equal-Weight | $18.00 | $20.00 |
| Richard Hill | Morgan Stanley | Lowers | Overweight | $21.00 | $22.00 |
| Omotayo Okusanya | Deutsche Bank | Lowers | Hold | $18.00 | $28.00 |
| Amanda Sweitzer | Baird | Lowers | Outperform | $21.00 | $22.00 |
| Nicholas Yulico | Scotiabank | Lowers | Sector Perform | $19.00 | $21.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Healthpeak Properties's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Healthpeak Properties analyst ratings.
Healthpeak owns a diversified healthcare portfolio of approximately 700 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Healthpeak Properties's financials over 3M reveals challenges. As of 30 June, 2025, the company experienced a decline of approximately -0.17% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Healthpeak Properties's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Healthpeak Properties's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.39%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Healthpeak Properties's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.16%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Healthpeak Properties's debt-to-equity ratio is below the industry average at 1.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: DOC